Changes in peripheral lymphocyte populations in patients with advanced/recurrent ovarian cancer undergoing splenectomy during cytoreductive surgery

[1]  S. Goswami,et al.  Highly immunosuppressive HLADRhi regulatory T cells are associated with unfavorable outcomes in cervical squamous cell carcinoma , 2019, International journal of cancer.

[2]  R. Oba,et al.  Circulating CD3+HLA-DR+ Extracellular Vesicles as a Marker for Th1/Tc1-Type Immune Responses , 2019, Journal of immunology research.

[3]  Ge Chen,et al.  Splenectomy during cytoreductive surgery in epithelial ovarian cancer , 2018, Cancer management and research.

[4]  G. Rijkers,et al.  Persistent changes in circulating white blood cell populations after splenectomy , 2018, International Journal of Hematology.

[5]  F. Wang,et al.  Changes in regulatory T cells in patients with ovarian cancer undergoing surgery: Preliminary results , 2017, International immunopharmacology.

[6]  Kimberly R. Jordan,et al.  Immunosuppressive myeloid-derived suppressor cells are increased in splenocytes from cancer patients , 2017, Cancer Immunology, Immunotherapy.

[7]  Zong-fang Li,et al.  Effect of Splenectomy Combined with Resection for Gastric Carcinoma on Patient Prognosis , 2016, Medical science monitor : international medical journal of experimental and clinical research.

[8]  Xuxia Shen,et al.  Distal pancreatectomy with splenectomy for the management of splenic hilum metastasis in cytoreductive surgery of epithelial ovarian cancer , 2016, Journal of gynecologic oncology.

[9]  L. Bixby,et al.  A Strong B-cell Response Is Part of the Immune Landscape in Human High-Grade Serous Ovarian Metastases , 2016, Clinical Cancer Research.

[10]  A. Jemal,et al.  Cancer statistics in China, 2015 , 2016, CA: a cancer journal for clinicians.

[11]  A. Azmi,et al.  Immune evasion in cancer: Mechanistic basis and therapeutic strategies. , 2015, Seminars in cancer biology.

[12]  L. Jeng,et al.  Splenectomy and increased subsequent cancer risk: a nationwide population-based cohort study. , 2015, American journal of surgery.

[13]  A. Jemal,et al.  Global cancer statistics, 2012 , 2015, CA: a cancer journal for clinicians.

[14]  R. Ferris,et al.  PD-1/SHP-2 inhibits Tc1/Th1 phenotypic responses and the activation of T cells in the tumor microenvironment. , 2015, Cancer research.

[15]  L. Levy,et al.  Splenectomy inhibits non-small cell lung cancer growth by modulating anti-tumor adaptive and innate immune response , 2015, Oncoimmunology.

[16]  J. Long,et al.  Abnormal distribution of peripheral lymphocyte subsets induced by PDAC modulates overall survival. , 2014, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].

[17]  Wang-Yu Zhu,et al.  Changes of CD4+CD25+FOXP3+ and CD8+CD28- regulatory T cells in non-small cell lung cancer patients undergoing surgery. , 2014, International immunopharmacology.

[18]  R. Hoover,et al.  Long-term risks after splenectomy among 8,149 cancer-free American veterans: a cohort study with up to 27 years follow-up , 2014, Haematologica.

[19]  Jaime Prat,et al.  Staging classification for cancer of the ovary, fallopian tube, and peritoneum , 2014, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[20]  R. Morgan,et al.  B cell regulation of anti-tumor immune response , 2013, Immunologic Research.

[21]  E. Podack,et al.  B cell regulation of anti-tumor immune response , 2013, Immunologic Research.

[22]  J. Ochando,et al.  Immune tolerance to tumor antigens occurs in a specialized environment of the spleen. , 2012, Cell reports.

[23]  A. Brożyna,et al.  Analysis of Treg Cell Population Alterations in the Peripheral Blood of Patients Treated Surgically for Ovarian Cancer – A Preliminary Report , 2011, American journal of reproductive immunology.

[24]  Hui Liu,et al.  Role of CD4+CD25+ Regulatory T Cells in Melatonin‐Mediated Inhibition of Murine Gastric Cancer Cell Growth In Vivo and In Vitro , 2011, Anatomical record.

[25]  J. Schorge,et al.  Prognostic Significance of Splenectomy as Part of Initial Cytoreductive Surgery in Ovarian Cancer , 2011, Annals of Surgical Oncology.

[26]  G. Kenter,et al.  Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. , 2010, The New England journal of medicine.

[27]  B. Chauffert,et al.  CD4+CD25+ Tregs control the TRAIL-dependent cytotoxicity of tumor-infiltrating DCs in rodent models of colon cancer. , 2008, The Journal of clinical investigation.

[28]  R. Barakat,et al.  The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer. , 2008, Gynecologic oncology.

[29]  R. Prehn.  The paradoxical effects of splenectomy on tumor growth , 2006, Theoretical Biology and Medical Modelling.

[30]  M. Manns,et al.  Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. , 2005, Cancer research.

[31]  L. Gergely,et al.  Can CD3+/HLA-DR+ activated T cells predict the prognosis of non-Hodgkin's lymphoma patients? , 2005, Immunology letters.

[32]  M. Feuerer,et al.  Treg Cell Differentiation: From Thymus to Peripheral Tissue. , 2015, Progress in molecular biology and translational science.

[33]  Figo Guidelines.  Staging classification for cancer of the ovary, fallopian tube, and peritoneum☆ , 2013 .

[34]  I. Nagata,et al.  Changes of lymphocyte subsets in peripheral blood before and after operation of patients with advanced ovarian carcinoma , 2005, Journal of Cancer Research and Clinical Oncology.

[35]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.